<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: <z:chebi fb="0" ids="2663">Amiodarone</z:chebi> is frequently associated with thyroid dysfunction </plain></SENT>
<SENT sid="1" pm="."><plain>Identifying predictors for <z:chebi fb="0" ids="2663">amiodarone</z:chebi>-associated thyroid dysfunction and assessing treatment outcome may aid clinicians in daily practice </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: We included 303 consecutive patients with <z:chebi fb="0" ids="2663">amiodarone</z:chebi> therapy for <z:hpo ids='HP_0011675'>cardiac arrhythmias</z:hpo> (260 with <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> and 43 with <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo>) </plain></SENT>
<SENT sid="3" pm="."><plain>Thyroid function tests were performed every 6 months </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Mean age was 63 ± 12 years and 66% was male </plain></SENT>
<SENT sid="5" pm="."><plain>After median follow-up of 3·3 (0·1-24) years, 23 (8%) patients developed <z:chebi fb="0" ids="2663">amiodarone</z:chebi>-associated <z:e sem="disease" ids="C0040156" disease_type="Disease or Syndrome" abbrv="">thyrotoxicosis</z:e> (incidence rate 1·9 per 100 person years) and 18 (6%) <z:hpo ids='HP_0000821'>hypothyroidism</z:hpo> (incidence rate 1·1 per 100 person years) </plain></SENT>
<SENT sid="6" pm="."><plain>The only predictor for <z:chebi fb="0" ids="2663">amiodarone</z:chebi>-associated <z:e sem="disease" ids="C0040156" disease_type="Disease or Syndrome" abbrv="">thyrotoxicosis</z:e> was age &lt;62 years [HR = 2·4 (95% CI 1·0-5·7), P = 0·05] </plain></SENT>
<SENT sid="7" pm="."><plain>Predictors for <z:chebi fb="0" ids="2663">amiodarone</z:chebi>-associated <z:hpo ids='HP_0000821'>hypothyroidism</z:hpo> were thyroid stimulating hormone &gt;1·4 mU/l at baseline [HR = 5·1 (95% CI 1·1-22·4), P = 0·03], left ventricular ejection fraction &lt;45% [HR = 3·8 (95% CI 1·1-13·3), P = 0·04] and <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> at baseline [HR = 3·3 (95% CI 1·1-10·3), P = 0·04] </plain></SENT>
<SENT sid="8" pm="."><plain>Gender was not a predictor for <z:chebi fb="0" ids="2663">amiodarone</z:chebi>-associated thyroid dysfunction </plain></SENT>
<SENT sid="9" pm="."><plain>Five out of 12 (42%) patients with <z:e sem="disease" ids="C0040156" disease_type="Disease or Syndrome" abbrv="">thyrotoxicosis</z:e> exhibited spontaneous normalization of thyroid function on continuation of <z:chebi fb="0" ids="2663">amiodarone</z:chebi> therapy </plain></SENT>
<SENT sid="10" pm="."><plain>Mean time to normalization in the total group was 6·2 ± 3·3 months, with no difference between continuing or discontinuing <z:chebi fb="0" ids="2663">amiodarone</z:chebi> (6·6 ± 3·8 vs 5·8 ± 2·8 months, P = 0·5) </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: During median follow-up of 3·3 years, the incidence of <z:chebi fb="0" ids="2663">amiodarone</z:chebi>-associated <z:e sem="disease" ids="C0040156" disease_type="Disease or Syndrome" abbrv="">thyrotoxicosis</z:e> was higher compared to <z:hpo ids='HP_0000821'>hypothyroidism</z:hpo> </plain></SENT>
<SENT sid="12" pm="."><plain>Only general predictors for <z:chebi fb="0" ids="2663">amiodarone</z:chebi>-associated thyroid dysfunction were observed </plain></SENT>
<SENT sid="13" pm="."><plain>Discontinuation of <z:chebi fb="0" ids="2663">amiodarone</z:chebi> did not influence treatment outcome </plain></SENT>
</text></document>